Nasdaq panel grants Citius Pharma extension to regain bid price compliance by Dec 3, 2024

Citius Pharmaceuticals, Inc.

Company received bid price deficiency notice on Sep 12, 2023, extended to Sep 9, 2024.
After failing to regain compliance, hearing requested and held on Oct 29, 2024.
Panel decision on Nov 6, 2024 grants continued listing subject to compliance deadline Dec 3, 2024.
Company must provide prompt notification of any significant events affecting compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.